A citation-based method for searching scientific literature

Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
Times Cited: 201



Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
Times Cited: 298




List of shared articles



Times cited

Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Arjun K Pandey, Iva Okaj, Hargun Kaur, Emilie P Belley-Cote, Jia Wang, Alireza Oraii, Alexander P Benz, Linda S B Johnson, Jack Young, Jorge A Wong,[...]. J Am Heart Assoc 2021
0

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis.
E G Dorsey-Treviño, J G González-González, N Alvarez-Villalobos, V González-Nava, B M Contreras-Garza, A Díaz González-Colmenero, G Rodríguez-Tamez, F J Barrera-Flores, A M Farrell, V M Montori,[...]. J Endocrinol Invest 2020
8


Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Cardiovasc Diabetol 2020
9

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians.
Awadhesh Kumar Singh, Ambika G Unnikrishnan, Abdul H Zargar, Ajay Kumar, Ashok K Das, Banshi Saboo, Binayak Sinha, Kalyan Kumar Gangopadhyay, Pradeep G Talwalkar, Samit Ghosal,[...]. Diabetes Ther 2019
9

Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i).
Stephen Brunton, Heather M Rozjabek, Dominic Pilon, Marie-Hélène Lafeuille, Rhiannon Kamstra, Willy Wynant, Brahim K Bookhart, Patrick Lefebvre. Curr Med Res Opin 2019
2

Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
Xiaoyu Li, Ting Li, Ying Cheng, Yunhong Lu, Mei Xue, Linxin Xu, Xiangyang Liu, Xiaochen Yu, Bei Sun, Liming Chen. Diabetes Metab Res Rev 2019
16

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou, Nikolaos Tentolouris. Int J Environ Res Public Health 2019
46

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.
Bryce C Simes, Gordon G MacGregor. Diabetes Metab Syndr Obes 2019
16

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang, Jun Liang. Medicine (Baltimore) 2019
24

Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents.
Yajing Zhang, Huazhuo Ban, Runan Yu, Zhijian Wang, Dayong Zhang. Future Med Chem 2018
6


Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Julio Rosenstock, Chantal Mathieu, Hungta Chen, Ricardo Garcia-Sanchez, Gabriela Luporini Saraiva. Arch Endocrinol Metab 2018
7

Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Vasilios Tsimihodimos, Theodosios D Filippatos, Moses S Elisaf. Expert Opin Drug Metab Toxicol 2017
14

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.
Amir Qaseem, Michael J Barry, Linda L Humphrey, Mary Ann Forciea, Nick Fitterman, Carrie Horwitch, Devan Kansagara, Robert M McLean, Timothy J Wilt. Ann Intern Med 2017
106

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court,[...]. Health Technol Assess 2017
27